The last decade has seen an emergence of multidrug-resistant (MDR) bacteria in community and hospital environments, enhanced by the broad misuse of antibiotics, resulting in a global public health issue.1 Considering the impact of antimicrobial resistance there is an urgent need for the development of novel antimicrobial agents. Bacteria can develop resistance easily to organic antimicrobial compounds compared to metal-based antimicrobials. This is due to bacterial metal import systems not being able to discriminate well between metal ions that are necessary for bacterial survival and ions that will harm them. Bacteria often require an exogenous iron source for their cellular activity. Ga(III) shares chemical similarities with iron(III) in charge, ionic radius and preferred coordination number therefore, it has become a potent inhibitor of important iron pathways. Unlike iron, Ga(III) is unable to be effectively reduced from 3+ to 2+ which is required for cellular iron pathways. Thus Ga(III) can be uptaken by bacterial cell instead of Fe(III) which leads to metabolic distress and cellular death.2 Several gallium(III) compounds are known to be effective antimicrobial agents with observed activity against multidrug resistant bacteria.3 We are interested to synthesise and evaluate the activity of novel Ga(III) fluoroquinolonate complexes towards MDR bacteria. The goal is to repurpose the quinolones, many of which are no longer effective toward MDR, by combining with a metal (gallium III) centre to reinvigorate their antibacterial activity. In this presentation, we report the synthesis, characterisation and evaluation of biological application of a series of heteroleptic Ga(III) complexes.